KRAS and neoplasm: Similarly, Martinez-Marti et al. [127] applied single-cell transcriptome sequencing to evaluate the distribution of cellular clones in xenograft tumor samples from mice treated with afatinib or capmatinib, uncovering the pivotal role of KRAS G12C mutation-driven tumor subclones in targeted therapy resistance.